Table 1.
Descriptive characteristics of the participants that received placebo in two different clinical trials (cohorts I and II)
| Variable | Cohort I (n = 13) | Cohort II (n = 12) | Total (n = 25) | |
|---|---|---|---|---|
| Sex | Male [n (%)] | 6 (46.2) | 3 (25.0) | 9 (36.0) |
| Female [n (%)] | 7 (53.8) | 9 (75.0) | 16 (64.0) | |
| Age | Mean (SD) | 37.8 (9.1) | 33.1 (12.1) | 35.6 (10.7) |
| Range (min–max) | 24–49 | 22–55 | 22–55 | |
| Subtype | Generalized [n (%)] | 9 (69.2) | 9 (75.0) | 18 (72.0) |
| Nongeneralized [n (%)] | 4 (30.8) | 3 (25.0) | 7 (28.0) | |
| CGI response | Responder [n (%)] | 5 (38.5) | 5 (41.7) | 10 (40.0) |
| Nonresponder [n (%)] | 8 (61.5) | 7 (58.3) | 15 (60.0) | |
| Genotype a | ||||
| 5-HTTLPR | ll [n (%)] | 4 (33.3) | 7 (58.3) | 11 (45.8) |
| s [n (%)] | 8 (67.7) | 5 (41.7) | 13 (54.2) | |
| TPH2 | GG [n (%)] | 8 (67.7) | 8 (67.7) | 16 (67.7) |
| T [n (%)] | 4 (33.3) | 4 (33.3) | 8 (33.3) | |
| 5-HTTLPR/TPH2 | ll/GG [n (%)] | 4 (33.3) | 5 (41.7) | 9 (37.5) |
| ll/T, s/T, s/GG [n (%)] | 8 (67.7) | 7 (58.3) | 15 (62.5) | |
| CGI responder by genotype | ||||
| 5-HTTLPR | ll [n (%)] | 1 (25.0) | 3 (42.8) | 4 (36.4) |
| s [n (%)] | 3 (37.5) | 2 (40.0) | 5 (38.5) | |
| TPH2 | GG [n (%)] | 3 (37.5) | 5 (62.5) | 8 (50.0) |
| T [n (%)] | 1 (25.0) | 0 (0) | 1 (12.5) | |
| 5-HTTLPR/TPH2 | ll/GG [n (%)] | 1 (25.0) | 3 (60.0) | 4 (44.4) |
| ll/T, s/T, s/GG [n (%)] | 3 (37.5) | 2 (28.6) | 5 (33.3) | |
aGenotyping was performed on 24 of the 25 subjects. 5-HTTLPR, Serotonin transporter polymorphism (ll, long allele homozygotes; s, short allele carriers); TPH2, tryptophan hydroxylase-2 gene (G allele homozygotes vs T allele carriers).